• Obviously. I’ve been reading about a market in the west hurt by lawsuits and the end of patents declining to spend so much time on research and development of new potential wonder drugs. Apparently the market is not so afflicted after all.

      This must be indicative of the westernization of medicine taking place in some developing countries. Their outcomes, that were surpassing those in the west (re: Mad In America, Robert Whitaker, 2002), are taking a nose dive because of the importation of western medicine.

      Here, real information about real adverse effects are likely to affect this expansion of the market, however, of course, the market is expected to expand.

      If the psych-drug market is suffering in the USA and Europe, no problem, the psych-drug industry has the entire developing world, where psych-drugs have not been employed so much, in which to peddle its wares, and successfully, it would seem, much to the detriment of the developing world.

      Report comment

  1. This is very sad. But, no doubt, the psychopharmacology profiteers are hell bent on exporting their scientifically invalid DSM iatrogenic illness creation system worldwide.

    How the game works, first, make as many millions of people “bipolar” with the ADHD drugs and antidepressants as you can. Then make them “psychotic,” via anticholinergic toxidrome, by adding the antipsychotics into the mix.


    Truly, it is shameful this is not being stopped. I guess at least the criminal doctors I dealt with will get to go home and attempt to murder their own people once they get out of jail.


    A little forewarning to the people of India.

    Report comment

  2. Yes it’s a real eye-opener. This “business intelligence” report makes chilling reading. For instance:

    “The neurology drugs market is expanding at a significant rate due to increasing prevalence of neurological disorders or injuries.”

    Note the spin towards ‘neurological’ rather than psychiatric or psychological. I see that a lot nowadays.

    “China and India are likely to be the fastest growing markets for antipsychotics in Asia. Key factors driving the antipsychotics market in emerging countries include presence of a large pool of patients, and rise in government funding.”

    Puts me in mind of “The mega-marketing of Depression in Japan” chapter from the book Crazy Like Us by Ethan Watters.

    “growing awareness regarding different neurological disorders and their available treatment are driving the global antipsychotics market.”

    Growing awareness? You bet! All those anti-stigma campaigns really paying dividends now.

    I fear this monstrous gravy train is unstoppable.

    Report comment